Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Quantitative PCR analysis for BcL-2/IgH in a phase III study of Yttrium-90 ibritumomab tiuxetan as consolidation of first remission in patients with follicular lymphoma
Journal of Clinical Oncology, 11/03/09

Goff L et al. – Eradication of PCR-detectable disease occurred more frequently after treatment with 90Y-ibritumomab tiuxetan and was associated with prolongation of PFS.

Methods

Blood samples from 414 patients (90Y-ibritumomab, n = 208; control, n = 206) were evaluated using real-time quantitative polymerase chain reaction (RQ-PCR); 186 were found to have the bcl-2 rearrangement and were thus eligible for inclusion in the RQ-PCR analysis

Results

90% of treated patients converted from bcl-2 PCR–detectable to –undetectable disease status, compared with 36% in control group
Treatment significantly prolonged median PFS in patients converting to bcl-2 PCR-undetectable status (40.8 v 24.0 months in the control group;hazard ratio [HR], 0.399)
In patients who had bcl-2 PCR-detectable disease at random assignment, treatment significantly prolonged median PFS (38.4 v 8.2 months in the control group; HR, 0.293)

<< Previous
The impact of carcinoembryonic antigen flare in patients with...

Next >>
Serum calcium levels are elevated among women with untreated...